D.E. Shaw & Co’s Pacira BioSciences PCRX Stock Holding History

D.E. Shaw & Co’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-35,700	Closed	-$3.17M	–	3904
2014 Q4	$3.17M	Sell	35,700 -23,000	-39%	-$2.18M	﹤0.01%	1900
2014 Q3	$5.69M	Buy	58,700 +25,700	+78%	+$2.5M	0.01%	1483
2014 Q2	$3.03M	Sell	33,000 -47,100	-59%	-$3.59M	﹤0.01%	1982
2014 Q1	$5.61M	Buy	80,100 +10,100	+14%	+$687K	0.01%	1496
2013 Q4	$4.02M	Buy	70,000 +30,000	+75%	+$1.58M	0.01%	1882
2013 Q3	$1.92M	Buy	40,000 +20,000	+100%	+$729K	﹤0.01%	2465
2013 Q2	$580K	Buy	+20,000	New	+$579K	﹤0.01%	3131

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's PCRX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Pacira BioSciences (PCRX) stake by 2.8% in Q1 2026, selling an estimated $1.27M and leaving 1,982,724 shares worth $44.8M. The position accounts for 0.03% of the portfolio, ranked #708.

D.E. Shaw & Co first reported a position in PCRX in Q2 2013 and has held it in 40 quarters since. The position peaked at $56.3M in Q1 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

D.E. Shaw & Co held 1,982,724 shares of Pacira BioSciences worth $44.8M as of Q1 2026.
D.E. Shaw & Co sold 57,203 Pacira BioSciences shares in Q1 2026, an estimated $1.27M.
Pacira BioSciences made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #708 holding.
D.E. Shaw & Co first reported a position in Pacira BioSciences in Q2 2013 and has held it in 40 quarters since.
D.E. Shaw & Co's Pacira BioSciences position peaked at $56.3M in Q1 2025.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.